Combined-modality therapy of locally advanced non-small-cell lung cancer

ONCOLOGY

Volumn 11, Issue 9 SUPPL., 1997, Pages 43-50

  Wagner, Henry ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; VINDESINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; TREATMENT PLANNING; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PILOT PROJECTS; RADIATION DOSAGE; RANDOMIZED CONTROLLED TRIALS;

EID: 9844239914     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wingo PA, Tong T, Bolden S: Cancer statistics CA Cancer J Clin 45:8-30, 1995
2. Perez CA, Stanley H, Rubin P, et al: A prospective randomized study of various radiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung. Cancer 45:2744-2753, 1980.
3. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone vs combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer. First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991.
4. Finkelstein DM, Ettinger DS, Ruckdeschel, JC: Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 4:702-709, 1986.
5. Mountain CF: A new international staging system for lung cancer. Chest 89:2255-2335, 1986 (suppl).
6. Curran WJ, Stafford PM Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy. J Clin Oncol 8:409-415, 1990.
7. Bonomi P, Gale M, Rowland K, et al: Pretreatment prognostic factors in stage III non-small-cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys 20:247-252, 1990.
8. Dillman RO, Seagren SL, Herndon J, et al: Randomized trial of induction chemotherapy plus high dose radiotherapy vs radiation therapy alone in stage III non-small-cell lung cancer: Five-year follow-up of CALGB 8433 [Abstract]. Proc Am Soc Clin Oncol 12:329, 1993.
9. Lung Cancer Study Group: Should subcarinal lymph nodes be routinely examined in patients with non-small-cell lung cancer? J Thorac Cardiovasc Surg 95:883-887, 1988.
10. Green M, Lilenbaum R: Stage IIIA category of non-small-cell lung cancer: A new proposal. J Natl Cancer Inst 86:586-588, 1994.
11. Patterson GA, Ginsberg RJ, Poon PY, et al: A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 94:679-684, 1987.
12. Le Chevalier T, Arriagada R, Tarayre M, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma (letter). J Natl Cancer Inst 84:58, 1992.
13. Boxwala A, Rosenman JG: Retrospective reconstruction of three-dimensional radiotherapy treatment plans from two-dimensional planning data. Int J Radiat Oncol Biol Phys 28:1009-1015, 1994.
14. Lawrence TS, Kessler ML, Ten Haken RK: Clinical interpretation of dose-volume histograms: The basis for normal tissue preservation and tumor dose escalation. Front Radiat Ther Oncol 29:57-66, 1996.
15. Graham MV, Purdy JA, Emami B, et al: 3-D conformal radiotherapy for lung cancer. From Radiat Ther Oncol 29:188-198, 1996.
16. Leibel SA, Armstrong JG, Kutcher GJ, et al: 3-D conformal radiation therapy for non-small-cell lung carcinoma. Front Radiat Ther Oncol 29:199-206, 1996.
17. Hazuka MB, Turrisi AT, Lutz ST, et al: Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small-cell lung cancer. A retrospective multivariate analysis. Int J Radiat Oncol Biol Phys 27:273-284, 1993.
18. Emami B, Scott C, Byhardt R, et al: The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small-cell lung cancer: An RTOG analysis (abstract 102). Int J Radiat Oncol Biol Phys 36 (suppl):209, 1996.
19. Fowler JF: Fractionation in radiation therapy. Semin Radiat Oncol 2:16-21, 1992.
20. Withers MR, Thomas MD, Peters LJ: Differences in the fractionation response of acutely and late responding tissues, in Kaercher KM, Kogelnik D, Reinartz G (eds): Progress in Radio-Oncology, vol 1, p 287. New York, Raven Press, 1982.
21. Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiotherapy with total doses of 60.0 Gy to 79.2 Gy. Possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung cancer - Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1553, 1990.
22. Sause WT, Scott CB, Taylor S, et al: RTOG 8808, ECOG 4588: Preliminary analysis of a phase III trial in regionally advanced non-small-cell lung cancer with minimum three-year follow-up Int J Radiat Oncol Biol Phys 32:108-109, 1995 (suppl 1).
23. Saunders MI, Dische S: Continuous, hyperfractionated, accelerated radiation therapy (CHART) in non-small-cell carcinoma of the bronchus Int J Radiat Oncol Biol Phys 19:1211-1215, 1990.
24. Saunders M, Dische S, Barrett A, et al: Randomized multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report. CHART Steering Committee. Br J Cancer 73:1455-1462, 1966.
25. Tannehill SP, Froseth C, Wagner H, et al: Phase II trial of hyperfractionated accelerated radiation therapy (HART) for unresectable non-small-cell lung cancer: Preliminary results of ECOG 4593 (abstract 98). Int J Radiat Oncol Biol Phys 36(suppl):207, 1996.
26. Murray N, Coy P, Pater IL, et al: Importance of timing for thoracic irradiation in the combined-modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336-344, 1993.
27. Akerley W, Choy H, Glantz M, et al: Weekly pachtaxel for metastatic non-small-cell lung cancer (NSCLC)(abstract 1122). Proc Am Soc Clin Oncol 15:377, 1996.
28. Johnson DH, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small-cell lung cancer. Ann Intern Med 113:33-38, 1990.
29. Kubota K, Furuse K, Kawahara M, et al: Role of radiotherapy in combined-modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 12:1547-1552, 1994.
30. Ansari R, Tokar SR, Fisher W, et al: A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small-cell lung cancer (NSCLC): A Hoosier Oncology Group (HOG) protocol [Abstract 823]. Proc Am Soc Clin Oncol 10:241, 1991.
31. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer J Clin Oncol 13:452-458, 1995.
32. Schaake-Koning C, van der Bogaert T, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy in inoperable lung cancer. N Engl J Med 326:524-530, 1992.
33. Trovo M, Minatel E, Franchin G, et al: Radiotherapy vs radiotherapy enhanced by cisplatin in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 24:11-14, 1992.
34. Soresi E, Clerici M, Grilli R, et al: A randomized clinical trial comparing radiation therapy vs radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small-cell lung cancer. Semin Oncol 15:20-25, 1988 (suppl)